AbbVie's Routine Dividend Hides a Payout That Survived a Drug Cliff

Every quarter the board of AbbVie does something almost comically boring: it declares a dividend. In June it announced $1.73 a share, payable in August. No headline worth a second glance. But a routine dividend declaration is the best question you can ask about any income stock, because the check only means something if the business under it keeps earning what it needs to write it. On that question, AbbVie has a genuinely good story — and it has nothing to do with the quarterly press release.

A dividend is only as safe as the business writing it

A dividend is not a promise the company makes to you. It's a claim on cash it has to generate every single year, and the day that stops, the board either shrinks the check or cuts it entirely. So the real test of an income stock is simple: what happens to the payout when the business gets hit? AbbVie has now lived through about as hard a hit as a drugmaker can face, and the dividend is still growing.

When AbbVie was carved out of Abbott in 2013, its cash cow was Humira, at one point the best-selling medicine on the planet. Then its patents lapsed in the United States and Europe, and biosimilar copycats moved in. Humira has dwindled to about $756 million a quarter, down 36% from a year ago in the most recent period — a small fraction of a company that now books nearly $17 billion a quarter. For most pharmaceutical companies, losing your flagship drug is exactly how dividend cuts happen. AbbVie instead kept raising its payout. Since 2013 the dividend has grown by more than 330%, and the stock is a member of the S&P Dividend Aristocrats index, which tracks companies that have increased their dividend in each of at least 25 consecutive years.

How the payout actually survived

The reason the dividend held up is that AbbVie didn't defend the old drug — it replaced it. Two newer immunology treatments, Skyrizi and Rinvoq, have become Humira's successors and now drive the portfolio. In the second quarter Skyrizi booked $5.51 billion, up 24%, and Rinvoq $2.53 billion, up 25%, while the whole immunology franchise grew 15% and total revenue rose 10% to about $16.99 billion. Adjusted EPS climbed 23% to $3.65. That is double-digit growth from a company on the other side of a patent cliff — not the profile investors usually associate with a dividend that's at risk.

The funding check matters more than the growth, and this is where the accounting gets subtle enough to fool a careful reader. A screen will tell you AbbVie's payout ratio is absurdly high — somewhere north of 250% — and that any dividend paying out more than it earns is doomed. That number divides the dividend by GAAP earnings, which were just $2.36 a share last year, dragged down by charges tied to acquisitions and early-stage research spending. Divide the same dividend by the $10.00 a share the company actually manages for, and the 2025 payout was a healthy figure around 60%. Looking forward, the new dividend annualizes to $6.92 a share against guidance of $13.87 to $14.07 in adjusted earnings for 2026 — roughly half the profit, and comfortably covered.

The cash-flow check agrees. Free cash flow has been running near $18 billion a year against a dividend bill in the low teens of billions, so the payout clears the cash that funds it by a wide margin. That is the durability test a dividend investor should actually run, and AbbVie passes it.

What you pay, and what could break

At a price around $255, AbbVie trades at roughly 18 times its 2026 adjusted earnings — not cheap, but a moderate multiple for a business growing earnings in the low double digits, and far below the triple-digit price-to-earnings ratio the headline GAAP number suggests. That yield of about 2.7%, paired with double-digit growth, sits in the sweet spot where a modest starting yield can compound into meaningful income over time.

Two things could change the picture. First, this is now a concentrated story: Skyrizi and Rinvoq are both the growth engine and the risk. If rebate pressure or new competition cools that 24% pace, the double-digit growth that supports the premium multiple slows with it. Second, some of the growth is bought rather than earned organically — the planned acquisition of Apogee Therapeutics is itself dilutive to 2026 earnings by $0.14 a share. And the wide gap between GAAP profit and the dividend is worth watching: the cushion rests on treating acquisition and research spending as one-time items, and if those keep recurring, part of the "adjusted" comfort is cosmetic.

The dividend is AbbVie's scoreboard, and on that scoreboard the streak is intact: raised every year since 2013, funded by a re-accelerating franchise rather than borrowed confidence. Plenty of investors chase the stock because it's a "dividend aristocrat" — but the aristocrat label is a consequence, not a cause. The judgment each reader makes is whether roughly 18 times earnings is a fair price for a franchise that replaced the most successful drug in history and kept growing. On the durability of the payout itself, the evidence is no longer the worry.